Inventor : K2LT Technology R&D Team   

Patent Assignee: K2 LT LAB, LLC 

Technical Field

The present invention relates to the technical field of preparations, and in particular to the medical application of a protein composition for treating Alzheimer's disease.

technical background

Alzheimer's disease is a multifactorial neurodegenerative disease with multiple causes. Due to the complexity of this disease, humans have not yet discovered effective therapeutic drugs.

The brains of people with Alzheimer's disease have at least nine types of changes:

(1) Amyloid-beta protein accumulates in the brain, causing amyloid plaque and leading to brain neurotoxicity.

(2) Tau protein accumulation, also known as neurofibrillary tangles, causes another type of brain neurotoxicity.

(3) Neuroinflammation caused by NF-kB (p65).

(4) ATP (energy source) decreases and leads to brain energy failure.

(5) Deposition of cellular beta-amyloid and tau proteins due to impairment of autophagy (the cell’s waste removal function).

(6) IL-6 (inflammatory factor) increased.

(7) Increased TNFα (inflammatory factor).

(8) p53 (lesion-controlling gene) dysfunction.

(9) SOD (used to reduce free radicals) dysfunction causes free radicals to accumulate in the brain.

Given the multiple etiological factors of Alzheimer's disease, the current approach of using drugs to target a single symptom may have little effect on patients, resulting in the recent failure of many clinical trials of new drugs for Alzheimer's disease.

Summary of the invention

However, we have discovered a protein peptide that may treat at least five types of Alzheimer's disease. So it may be the most effective and potential effective drug currently.

Our drug is an 11-amino acid protein peptide (designated AQ-3) that has five functions targeting Alzheimer’s disease-related features, including:

(1) AQ-3 can reduce the level of tau protein in the mouse brain by 27.5%, thereby reducing the neurotoxins caused by tau protein.

(2) AQ-3 can increase the glycolysis rate in the mouse brain by 44%, which can make up for the lack of ATP (energy) in the brain.

(3) As the glycolysis rate in the mouse brain increases, AQ-3 increases ATP in the mouse brain by 89.8%.

(4) AQ-3 can reduce p38 by 61%. p38 is a mediator of neurotoxin production by beta-amyloid protein in the mouse brain. AQ-3 reduces p38, so it can block the toxicity of betaamyloid.

(5) AQ-3 can reduce NF-kB p65, a mediator that causes neuroinflammation, by 49.4%, thereby reducing brain neuroinflammation.

(6) AQ-3 increases the gene expression of the autophagy gene ATG-5 by 109%. Therefore, AQ-3 can promote the removal of waste by brain cells.

However, no effect of this protein peptide on IL-6, TNF-α, brain p53 and SOD was observed.

Although it seems unlikely that a single protein peptide could have so many effects and various biological functions. However, after we studied the mechanism of action ( MOA) of this protein peptide, we found that this protein peptide is indeed likely to have multiple functions in biology. First, we found that this protein peptide is distributed in various organelles such as mitochondria and endoplasmic reticulum after entering the cell. Second, this protein peptide can inhibit various enzymes such as HDAC, glycokinase II, glucosamine and respiratory chains 1 and 3, and activate respiratory chain I in normal cells. At the gene expression level, this protein peptide increased the expression of energy production genes such as ACYL, UCP2 and PINK1, and autophagy genes such as ATG5 and ATG7.

The composition of the present invention has the following advantages

A medical application of a protein composition for treating Alzheimer's disease. We have discovered a protein peptide that may have the effect of treating Alzheimer's dementia. Alzheimer's disease is a brain disease caused by multiple factors. Generally, patients have at least nine lesions in their brains. Currently, dementia drugs developed by humans only treat one of the lesions, so the success rate is quite low. However, our protein peptide can treat seven lesions in the brain. Therefore, the effectiveness should be greatly improved.

The main component of the composition of this invention is the Turritopsis dohrnii, which has the ability to "reverse growth". German Max Planck scientists and professors from the Chinese Academy of Sciences have proved through experiments that the Turritopsis dohrnii is immortal. It transforms from one state to another. Let's assume that it transforms from adult to juvenile. Then its life state should be able to transform from adult to juvenile again. But it should be more accurate to say that it is "rejuvenation". Turritopsis dohrnii protein is the star patented component of this product. It has the effect of treating Alzheimer's dementia.

Main effects of the present invention

1. Repair brain cell DNA and enhance brain cell autophagy

2. Supplement protein and myelin, enhance cognitive ability, and stabilize emotions*

3. Help maintain the integrity and connection of brain cells and prevent Alzheimer's disease*

4. Helps Promote a Healthy Inflammatory Response and Supports Brain Health

Preparation:

1. Weigh appropriate amount of K2lt lab proprietary substance mixture, jellyfish protein and its auxiliary materials according to the mass fraction ratio ;

2. Plant extract, non-GMO, and gluten-free.

3. Stirring and mixing to obtain a protein composition for treating Alzheimer's disease;

This mixture is a concentrated essence oral liquid with excellent stability, no cross-linking reaction, Maillard reaction, condensation reaction; loose storage, transportation, use conditions and a large temperature and humidity range; suitable for all people, no religious belief risk;

In summary, a medical application of a protein composition for treating Alzheimer's disease can relieve senile dementia, promote brain nerve development, and improve the memory of the elderly. It helps maintain the integrity and connection of brain cells , prevents Alzheimer's disease, and supports brain health.